Executive Briefing - Health technology assessment: beyond economics?
This article was originally published in Scrip
Executive Summary
Novel pharmacological approaches can have a significant impact on a disease and offer great benefits to specific patient populations. However, where current treatments exist, payers and others are often sceptical as to the value of new ones, arguing that the new, patent-protected treatment commands a higher price for the same therapeutic effect.